Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Berthony Deslouches, Jonathan D. Steckbeck, Jodi K. Craigo, Yohei Doi, Jane L. Burns, Ronald C. Montelaro

研究成果: Article

60 引用 (Scopus)

抜粋

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

元の言語English
ページ(範囲)1329-1333
ページ数5
ジャーナルAntimicrobial agents and chemotherapy
59
発行部数2
DOI
出版物ステータスPublished - 01-02-2015
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用